Skip to Content Skip to Search

GSK supports recovery efforts to help those affected by the Japan earthquake

In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan's north east coastline region, GlaxoSmithKline (GSK) is supporting the ongoing relief efforts by working with the Japanese authorities, the Japan Pharmaceutical Manufacturers Association and local NGOs to assist medical support and pharmaceutical donation needs.

Issued: London UK

In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan’s north east coastline region, GlaxoSmithKline (GSK) is supporting the ongoing relief efforts by working with the Japanese authorities, the Japan Pharmaceutical Manufacturers Association and local NGOs to assist medical support and pharmaceutical donation needs.

As part of the disaster relief program, GSK is donating ¥200 million (approx £1.5million) to the Japanese Red Cross to support the immediate efforts to supply clean water, blankets and food supplies.

The company is also donating cold medicines and oral care products worth ¥ 80 million (approx £600,000) following requests for this type of self-medication products from the authorities.

We are continuing to watch the situation closely and will provide additional support as the situation evolves. GSK is committed to supporting reconstruction efforts as much as possible.

The health and safety of all of the company’s staff based in Japan, particularly those working in the Tohoku region, was accounted for shortly after the earthquake and we continue to offer help and support to all our employees affected by this disaster.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GlaxoSmithKline enquiries:

   

UK Media enquiries:

David Mawdsley

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Janet Morgan

(020) 8047 5502

 

David Daley

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

 

Ziba Shamsi

(020) 8047 3289

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jeff McLaughlin

(215) 751 7002